Ocular Graft-Versus-Host Disease

The FDA has granted orphan drug designation to Cambium Medical Technologies’ fibrinogen-depleted human platelet lysate for the treatment of ocular graft-versus-host disease, according to a press release.

Ocugen has completed 50% of enrollment for a phase 3 trial of OCU300 for the treatment of ocular redness and discomfort in patients with ocular graft-versus-host disease, according to a press release.

In this video, Pooja Khandelwal, MD, an Associate Professor at the University of Cincinnati's Department of Pediatrics, discusses the challenges rising screen use has on the treatment of ocular graft-versus-host disease.